Journal of Psychopharmacology

Time course of pharmacokinetic and hormonal effects of inhaled high-dose salvinorin A in humans

open

Caspers, M. J., Griffiths, R. R., Johnson, M. W., MacLean, K. A., Prisinzano, T. E.

This open-label study (n=6) investigated the effects of vaporized Salvinorin A (1.26mg or 1.47mg/70kg) with regard to the pharmacokinetic time course of its availability in plasma concentration, subjective intensity ratings, and downstream hormonal effects. Results indicated that is plasma concentration and intensity of drug effects peaked at 2 minutes after inhalation. Salvinorin A increased prolactin (a hormone) 5 minutes after inhalation, whereas cortisol (another hormone) concentration was inconsistent and not well correlated with drug levels.

Abstract

Introduction: Salvinorin A is a kappa opioid agonist and the principal psychoactive constituent of the Salvia divinorum plant, which has been used for hallucinogenic effects. Previous research on salvinorin A pharmacokinetics likely underestimated plasma levels typically resulting from the doses administered due to inefficient vaporization and not collecting samples during peak drug effects.Method: Six healthy adults inhaled a single high dose of vaporized salvinorin A (n = 4, 21 mcg/kg; n = 2, 18 mcg/kg). Participant- and monitor-rated effects were assessed every 2 min for 60 min post-inhalation. Blood samples were collected at 13 time points up to 90 min post-inhalation.Results: Drug levels peaked at 2 min and then rapidly decreased. Drug levels were significantly, positively correlated with participant and monitor drug effect ratings. Significant elevations in prolactin were observed beginning 5 min post-inhalation and peaking at 15 min post-inhalation. Cortisol showed inconsistent increases across participants. Hormonal responses were not well correlated with drug levels.Discussion: This is the first study to demonstrate a direct relationship between changes in plasma levels of salvinorin A and drug effects in humans. The results confirm the efficacy of an inhalation technique for salvinorin A.